Bünyamin Yavuz1, Naim Ata2, Emre Oto3, Deniz Katircioglu-Öztürk3, Kudret Aytemir4, Banu Evranos4, Rasim Koselerli5, Emre Ertugay5, Abdulkadir Burkan5, Emrah Ertugay6, Christ P Gale7, A John Camm8, Ali Oto4. 1. Department of Cardiology, Medical Park Ankara Hospital, Ankara, Turkey. 2. Department of Internal Medicine, 29 Mayis Hospital, Ankara, Turkey. 3. MITS (Media and Medical Information Technology Solutions), Bilkent University Cyberpark, Ankara, Turkey. 4. Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. 5. Social Security Institution Ankara, Turkey. 6. Department of Business Administration, Faculty of Political Science, Ankara University, Ankara, Turkey. 7. Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. 8. Division of Clinical Sciences, Cardiovascular Sciences Research Centre, St George's, University of London, London, United Kingdom.
Abstract
AIMS: Although atrial fibrillation (AF) is increasingly common in developed countries, there is limited information regarding its demographics, co-morbidities, treatments and outcomes in the developing countries. We present the profile of the TuRkish Atrial Fibrillation (TRAF) cohort which provides real-life data about prevalence, incidence, co-morbidities, treatment, healthcare utilization and outcomes associated with AF. METHODS AND RESULTS: The TRAF cohort was extracted from MEDULA, a health insurance database linking hospitals, general practitioners, pharmacies and outpatient clinics for almost 100% of the inhabitants of the country. The cohort includes 507 136 individuals with AF between 2008 and 2012 aged >18 years who survived the first 30 days following diagnosis. Of 507 136 subjects, there were 423 109 (83.4%) with non-valvular AF and 84 027 (16.6%) with valvular AF. The prevalence was 0.80% in non-valvular AF and 0.28% in valvular AF; in 2012 the incidence of non-valvular AF (0.17%) was higher than valvular AF (0.04%). All-cause mortality was 19.19% (97 368) and 11.47% (58 161) at 1-year after diagnosis of AF. There were 35 707 (7.04%) ischaemic stroke/TIA/thromboembolism at baseline and 34 871 (6.87%) during follow-up; 11 472 (2.26%) major haemorrhages at baseline and 10 183 (2.01%) during follow-up, and 44 116 (8.69%) hospitalizations during the follow-up. CONCLUSION: The TRAF cohort is the first population-based, whole-country cohort of AF epidemiology, quality of care and outcomes. It provides a unique opportunity to study the patterns, causes and impact of treatments on the incidence and outcomes of AF in a developing country. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Although atrial fibrillation (AF) is increasingly common in developed countries, there is limited information regarding its demographics, co-morbidities, treatments and outcomes in the developing countries. We present the profile of the TuRkish Atrial Fibrillation (TRAF) cohort which provides real-life data about prevalence, incidence, co-morbidities, treatment, healthcare utilization and outcomes associated with AF. METHODS AND RESULTS: The TRAF cohort was extracted from MEDULA, a health insurance database linking hospitals, general practitioners, pharmacies and outpatient clinics for almost 100% of the inhabitants of the country. The cohort includes 507 136 individuals with AF between 2008 and 2012 aged >18 years who survived the first 30 days following diagnosis. Of 507 136 subjects, there were 423 109 (83.4%) with non-valvular AF and 84 027 (16.6%) with valvular AF. The prevalence was 0.80% in non-valvular AF and 0.28% in valvular AF; in 2012 the incidence of non-valvular AF (0.17%) was higher than valvular AF (0.04%). All-cause mortality was 19.19% (97 368) and 11.47% (58 161) at 1-year after diagnosis of AF. There were 35 707 (7.04%) ischaemic stroke/TIA/thromboembolism at baseline and 34 871 (6.87%) during follow-up; 11 472 (2.26%) major haemorrhages at baseline and 10 183 (2.01%) during follow-up, and 44 116 (8.69%) hospitalizations during the follow-up. CONCLUSION: The TRAF cohort is the first population-based, whole-country cohort of AF epidemiology, quality of care and outcomes. It provides a unique opportunity to study the patterns, causes and impact of treatments on the incidence and outcomes of AF in a developing country. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ali Coner; Cenk Ekmekci; Gokhan Aydin; Yasemin Kilavuz Dogan; Ozlem Arican Ozluk; Salih Kilic; Yunus Celik; Ismail Ungan; Mustafa Begenc Tascanov; Ramazan Duz; Veli Polat; Hakan Ozkan; Mehmet Ozyasar; Kamil Tuluce; Abdullah Icli; Devrim Kurt; Nurullah Cetin; Murat Gul; Sinan Inci; Mehdi Zoghi; Oktay Ergene; Ugur Onsel Turk Journal: J Atr Fibrillation Date: 2021-04-30
Authors: Begüm Sayın; Sercan Okutucu; Mehmet Birhan Yılmaz; Kurtuluş Özdemir; Ali Aydınlar; Durmuş Yıldıray Şahin; Armağan Altun; Sadık Açıkel; Ertuğrul Okuyan; Murat Sucu; Zeki Öngen; Murat Kazim Ersanlı; Özcan Yılmaz; Mesut Demir; Hasan Pekdemir; Ramazan Topsakal; Mehmet Levent Şahiner; Dursun Aras; Ali Oto Journal: Anatol J Cardiol Date: 2019-04 Impact factor: 1.596